Operating Income - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.2 PLN -0.18% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Operating Income Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Operating Income
-zł102.5m
CAGR 3-Years
-30%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Operating Income
-zł2.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-12%
M
Medicofarma Biotech SA
WSE:MDB
Operating Income
-zł2.5m
CAGR 3-Years
-60%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Operating Income
zł63m
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Operating Income?
Operating Income
-102.5m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Operating Income amounts to -102.5m PLN.

What is Ryvu Therapeutics SA's Operating Income growth rate?
Operating Income CAGR 5Y
-26%

Over the last year, the Operating Income growth was -16%. The average annual Operating Income growth rates for Ryvu Therapeutics SA have been -30% over the past three years , -26% over the past five years .

Back to Top